These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 17449723)

  • 1. The Troll in Toll: Mal and Tram as bridges for TLR2 and TLR4 signaling.
    Sheedy FJ; O'Neill LA
    J Leukoc Biol; 2007 Aug; 82(2):196-203. PubMed ID: 17449723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling.
    O'Neill LA; Bowie AG
    Nat Rev Immunol; 2007 May; 7(5):353-64. PubMed ID: 17457343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signalling adaptors used by Toll-like receptors: an update.
    Kenny EF; O'Neill LA
    Cytokine; 2008 Sep; 43(3):342-9. PubMed ID: 18706831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling.
    Carty M; Goodbody R; Schröder M; Stack J; Moynagh PN; Bowie AG
    Nat Immunol; 2006 Oct; 7(10):1074-81. PubMed ID: 16964262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral inhibitory peptide of TLR4, a peptide derived from vaccinia protein A46, specifically inhibits TLR4 by directly targeting MyD88 adaptor-like and TRIF-related adaptor molecule.
    Lysakova-Devine T; Keogh B; Harrington B; Nagpal K; Halle A; Golenbock DT; Monie T; Bowie AG
    J Immunol; 2010 Oct; 185(7):4261-71. PubMed ID: 20802145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signalling of toll-like receptors.
    Brikos C; O'Neill LA
    Handb Exp Pharmacol; 2008; (183):21-50. PubMed ID: 18071653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of the TIR domain-containing adaptors in humans: swinging between constraint and adaptation.
    Fornarino S; Laval G; Barreiro LB; Manry J; Vasseur E; Quintana-Murci L
    Mol Biol Evol; 2011 Nov; 28(11):3087-97. PubMed ID: 21659570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRAM is required for TLR2 endosomal signaling to type I IFN induction.
    Stack J; Doyle SL; Connolly DJ; Reinert LS; O'Keeffe KM; McLoughlin RM; Paludan SR; Bowie AG
    J Immunol; 2014 Dec; 193(12):6090-102. PubMed ID: 25385819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recipient Toll-like receptors contribute to chronic graft dysfunction by both MyD88- and TRIF-dependent signaling.
    Wang S; Schmaderer C; Kiss E; Schmidt C; Bonrouhi M; Porubsky S; Gretz N; Schaefer L; Kirschning CJ; Popovic ZV; Gröne HJ
    Dis Model Mech; 2010; 3(1-2):92-103. PubMed ID: 20038715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of pathogen-specific TLR4 activation in the mucosa: fimbriae, recognition receptors and adaptor protein selection.
    Fischer H; Yamamoto M; Akira S; Beutler B; Svanborg C
    Eur J Immunol; 2006 Feb; 36(2):267-77. PubMed ID: 16385628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expanding family of MyD88-like adaptors in Toll-like receptor signal transduction.
    McGettrick AF; O'Neill LA
    Mol Immunol; 2004 Jul; 41(6-7):577-82. PubMed ID: 15219996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARM inhibits both TRIF- and MyD88-mediated AP-1 activation.
    Peng J; Yuan Q; Lin B; Panneerselvam P; Wang X; Luan XL; Lim SK; Leung BP; Ho B; Ding JL
    Eur J Immunol; 2010 Jun; 40(6):1738-47. PubMed ID: 20306472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TICAM-1 and TICAM-2: toll-like receptor adapters that participate in induction of type 1 interferons.
    Seya T; Oshiumi H; Sasai M; Akazawa T; Matsumoto M
    Int J Biochem Cell Biol; 2005 Mar; 37(3):524-9. PubMed ID: 15618008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules.
    Matsunaga N; Tsuchimori N; Matsumoto T; Ii M
    Mol Pharmacol; 2011 Jan; 79(1):34-41. PubMed ID: 20881006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4.
    Pålsson-McDermott EM; O'Neill LA
    Immunology; 2004 Oct; 113(2):153-62. PubMed ID: 15379975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAPPIT analysis of early Toll-like receptor signalling events.
    Ulrichts P; Tavernier J
    Immunol Lett; 2008 Mar; 116(2):141-8. PubMed ID: 18221795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primer: Toll-like receptor signaling pathways--what do rheumatologists need to know?
    O'Neill LA
    Nat Clin Pract Rheumatol; 2008 Jun; 4(6):319-27. PubMed ID: 18446139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selenium suppresses the activation of transcription factor NF-kappa B and IRF3 induced by TLR3 or TLR4 agonists.
    Youn HS; Lim HJ; Choi YJ; Lee JY; Lee MY; Ryu JH
    Int Immunopharmacol; 2008 Mar; 8(3):495-501. PubMed ID: 18279804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caspase-1 targets the TLR adaptor Mal at a crucial TIR-domain interaction site.
    Ulrichts P; Bovijn C; Lievens S; Beyaert R; Tavernier J; Peelman F
    J Cell Sci; 2010 Jan; 123(Pt 2):256-65. PubMed ID: 20048342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ASC is essential for LPS-induced activation of procaspase-1 independently of TLR-associated signal adaptor molecules.
    Yamamoto M; Yaginuma K; Tsutsui H; Sagara J; Guan X; Seki E; Yasuda K; Yamamoto M; Akira S; Nakanishi K; Noda T; Taniguchi S
    Genes Cells; 2004 Nov; 9(11):1055-67. PubMed ID: 15507117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.